Additionally, Elotuzumab is an anti-SLAMF7 monoclonal antibody that is FDA-approved for the treatment of multiple myeloma (68, 69), raising the possibility that such drugs could also be used in the treatment of EBV-associated tumors with high SLAMF7 expression. This evidence concerns the gene SLAMF7 and AL amyloidosis.